

# HOUSE BILL 321

J5  
SB 626/24 – FIN

5lr2223  
CF SB 303

---

By: ~~Delegate Kipke~~ Delegates Kipke, Alston, Bagnall, Bhandari, Chisholm, Cullison, Guzzone, Hill, Hutchinson, S. Johnson, Kaiser, Kerr, Lopez, Martinez, M. Morgan, Pena-Melnyk, Reilly, Szeliga, White Holland, Woods, and Woorman

Introduced and read first time: January 10, 2025  
Assigned to: Health and Government Operations

---

Committee Report: Favorable with amendments  
House action: Adopted  
Read second time: February 11, 2025

---

## CHAPTER \_\_\_\_\_

1 AN ACT concerning

2 **Pharmacy Benefits Managers – Definition of Purchaser and Alteration of**  
3 **Application of Law**

4 FOR the purpose of altering the definition of “purchaser” for the purpose of certain  
5 provisions of State insurance law governing pharmacy benefits managers to exclude  
6 certain nonprofit health maintenance organizations; repealing certain provisions  
7 that restrict the applicability of certain provisions of law to pharmacy benefits  
8 managers that provide pharmacy benefits management services on behalf of a  
9 carrier; requiring the Maryland Insurance Administration to convene a workgroup  
10 to review and make recommendations on certain provisions of law regarding  
11 pharmacy benefits managers, specialty pharmacies, and antisteering; and generally  
12 relating to pharmacy benefits managers.

13 BY repealing and reenacting, with amendments,  
14 Article – Insurance  
15 Section 15–1601, 15–1611, 15–1611.1, 15–1612, 15–1622, 15–1629, and  
16 15–1630  
17 Annotated Code of Maryland  
18 (2017 Replacement Volume and 2024 Supplement)

19 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
20 That the Laws of Maryland read as follows:

---

### EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

~~Strike out~~ indicates matter stricken from the bill by amendment or deleted from the law by amendment.



## Article – Insurance

1

2 15–1601.

3 (a) In this subtitle the following words have the meanings indicated.

4 (b) “Agent” means a pharmacy, a pharmacist, a mail order pharmacy, or a  
5 nonresident pharmacy acting on behalf or at the direction of a pharmacy benefits manager.6 (c) “Beneficiary” means an individual who receives prescription drug coverage or  
7 benefits from a purchaser.8 (d) (1) “Carrier” means the State Employee and Retiree Health and Welfare  
9 Benefits Program, an insurer, a nonprofit health service plan, or a health maintenance  
10 organization that:

11 (i) provides prescription drug coverage or benefits in the State; and

12 (ii) enters into an agreement with a pharmacy benefits manager for  
13 the provision of pharmacy benefits management services.14 (2) “Carrier” does not include a person that provides prescription drug  
15 coverage or benefits through plans subject to ERISA and does not provide prescription drug  
16 coverage or benefits through insurance, unless the person is a multiple employer welfare  
17 arrangement as defined in § 514(b)(6)(A)(ii) of ERISA.18 (e) “Compensation program” means a program, policy, or process through which  
19 sources and pricing information are used by a pharmacy benefits manager to determine the  
20 terms of payment as stated in a participating pharmacy contract.21 (f) “Contracted pharmacy” means a pharmacy that participates in the network of  
22 a pharmacy benefits manager through a contract with:

23 (1) the pharmacy benefits manager; or

24 (2) a pharmacy services administration organization or a group purchasing  
25 organization.

26 (g) “ERISA” has the meaning stated in § 8–301 of this article.

27 (h) “Formulary” means a list of prescription drugs used by a purchaser.

28 (i) (1) “Manufacturer payments” means any compensation or remuneration a  
29 pharmacy benefits manager receives from or on behalf of a pharmaceutical manufacturer.

30 (2) “Manufacturer payments” includes:

1 (i) payments received in accordance with agreements with  
2 pharmaceutical manufacturers for formulary placement and, if applicable, drug utilization;

3 (ii) rebates, regardless of how categorized;

4 (iii) market share incentives;

5 (iv) commissions;

6 (v) fees under products and services agreements;

7 (vi) any fees received for the sale of utilization data to a  
8 pharmaceutical manufacturer; and

9 (vii) administrative or management fees.

10 (3) "Manufacturer payments" does not include purchase discounts based on  
11 invoiced purchase terms.

12 (j) "Nonprofit health maintenance organization" has the meaning stated in §  
13 6–121(a) of this article.

14 (k) "Nonresident pharmacy" has the meaning stated in § 12–403 of the Health  
15 Occupations Article.

16 (l) "Participating pharmacy contract" means a contract filed with the  
17 Commissioner in accordance with § 15–1628(b) of this subtitle.

18 (m) "Pharmacist" has the meaning stated in § 12–101 of the Health Occupations  
19 Article.

20 (n) "Pharmacy" has the meaning stated in § 12–101 of the Health Occupations  
21 Article.

22 (o) "Pharmacy and therapeutics committee" means a committee established by a  
23 pharmacy benefits manager to:

24 (1) objectively appraise and evaluate prescription drugs; and

25 (2) make recommendations to a purchaser regarding the selection of drugs  
26 for the purchaser's formulary.

27 (p) (1) "Pharmacy benefits management services" means:

28 (i) the procurement of prescription drugs at a negotiated rate for  
29 dispensation within the State to beneficiaries;

1 (ii) the administration or management of prescription drug coverage  
2 provided by a purchaser for beneficiaries; and

3 (iii) any of the following services provided with regard to the  
4 administration of prescription drug coverage:

5 1. mail service pharmacy;

6 2. claims processing, retail network management, and  
7 payment of claims to pharmacies for prescription drugs dispensed to beneficiaries;

8 3. clinical formulary development and management services;

9 4. rebate contracting and administration;

10 5. patient compliance, therapeutic intervention, and generic  
11 substitution programs; or

12 6. disease management programs.

13 (2) “Pharmacy benefits management services” does not include any service  
14 provided by a nonprofit health maintenance organization that operates as a group model,  
15 provided that the service:

16 (i) is provided solely to a member of the nonprofit health  
17 maintenance organization; and

18 (ii) is furnished through the internal pharmacy operations of the  
19 nonprofit health maintenance organization.

20 (q) “Pharmacy benefits manager” means a person that performs pharmacy  
21 benefits management services.

22 (r) “Proprietary information” means:

23 (1) a trade secret;

24 (2) confidential commercial information; or

25 (3) confidential financial information.

26 (s) **(1)** “Purchaser” means a person that offers a plan or program in the State,  
27 including the State Employee and Retiree Health and Welfare Benefits Program, **AN**  
28 **INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE**  
29 **ORGANIZATION**, that:

1            [(1)] (I) provides prescription drug coverage or benefits in the State; and

2            [(2)] (II) enters into an agreement with a pharmacy benefits manager for  
3 the provision of pharmacy benefits management services.

4            **(2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH**  
5 **MAINTENANCE ORGANIZATION THAT:**

6                            **(I) OPERATES AS A GROUP MODEL;**

7                            **(II) PROVIDES SERVICES SOLELY TO MEMBERS OR PATIENTS OF**  
8 **THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND**

9                            **(III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY**  
10 **OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.**

11            (t) “Rebate sharing contract” means a contract between a pharmacy benefits  
12 manager and a purchaser under which the pharmacy benefits manager agrees to share  
13 manufacturer payments with the purchaser.

14            (u) (1) “Therapeutic interchange” means any change from one prescription  
15 drug to another.

16                            (2) “Therapeutic interchange” does not include:

17                            (i) a change initiated pursuant to a drug utilization review;

18                            (ii) a change initiated for patient safety reasons;

19                            (iii) a change required due to market unavailability of the currently  
20 prescribed drug;

21                            (iv) a change from a brand name drug to a generic drug in accordance  
22 with § 12–504 of the Health Occupations Article; or

23                            (v) a change required for coverage reasons because the originally  
24 prescribed drug is not covered by the beneficiary’s formulary or plan.

25            (v) “Therapeutic interchange solicitation” means any communication by a  
26 pharmacy benefits manager for the purpose of requesting a therapeutic interchange.

27            (w) “Trade secret” has the meaning stated in § 11–1201 of the Commercial Law  
28 Article.

29 15–1611.

1 (a) [This section applies only to a pharmacy benefits manager that provides  
2 pharmacy benefits management services on behalf of a carrier.

3 (b)] A pharmacy benefits manager may not prohibit a pharmacy or pharmacist  
4 from:

5 (1) providing a beneficiary with information regarding the retail price for  
6 a prescription drug or the amount of the cost share for which the beneficiary is responsible  
7 for a prescription drug;

8 (2) discussing with a beneficiary information regarding the retail price for  
9 a prescription drug or the amount of the cost share for which the beneficiary is responsible  
10 for a prescription drug; or

11 (3) if a more affordable drug is available than one on the purchaser's  
12 formulary and the requirements for a therapeutic interchange under §§ 15–1633.1 through  
13 15–1639 of this subtitle are met, selling the more affordable alternative to the beneficiary.

14 [(c)] (B) This section may not be construed to alter the requirements for a  
15 therapeutic interchange under §§ 15–1633.1 through 15–1639 of this subtitle.

16 15–1611.1.

17 (a) [This section applies only to a pharmacy benefits manager that provides  
18 pharmacy benefits management services on behalf of a carrier.

19 (b)] Except as provided in subsection [(c)] (B) of this section, a pharmacy benefits  
20 manager may not require that a beneficiary use a specific pharmacy or entity to fill a  
21 prescription if:

22 (1) the pharmacy benefits manager or a corporate affiliate of the pharmacy  
23 benefits manager has an ownership interest in the pharmacy or entity; or

24 (2) the pharmacy or entity has an ownership interest in the pharmacy  
25 benefits manager or a corporate affiliate of the pharmacy benefits manager.

26 [(c)] (B) A pharmacy benefits manager may require a beneficiary to use a  
27 specific pharmacy or entity for a specialty drug as defined in § 15–847 of this title.

28 15–1612.

29 (a) [This section applies only to a pharmacy benefits manager that provides  
30 pharmacy benefits management services on behalf of a carrier.

31 (b)] This section does not apply to reimbursement:

1 (1) for specialty drugs;

2 (2) for mail order drugs; or

3 (3) to a chain pharmacy with more than 15 stores or a pharmacist who is  
4 an employee of the chain pharmacy.

5 **[(c)] (B)** A pharmacy benefits manager may not reimburse a pharmacy or  
6 pharmacist for a pharmaceutical product or pharmacist service in an amount less than the  
7 amount that the pharmacy benefits manager reimburses itself or an affiliate for providing  
8 the same product or service.

9 15–1622.

10 **[(a)]** Except as provided for in subsection (b) of this section, the provisions of §§  
11 15–1623 and 15–1624 of this subtitle apply only to a pharmacy benefits manager that  
12 provides pharmacy benefits management services on behalf of a carrier.

13 **[(b)]** The provisions of §§ 15–1623 and 15–1624 of this part do not apply to a  
14 pharmacy benefits manager when providing pharmacy benefits management services to a  
15 purchaser that is affiliated with the pharmacy benefits manager through common  
16 ownership within an insurance holding company.

17 15–1629.

18 **[(a)]** **[(C)]** [This section applies only to a pharmacy benefits manager that provides  
19 pharmacy benefits management services on behalf of a carrier.

20 **[(b)]** This section does not apply to an audit that involves probable or potential  
21 fraud or willful misrepresentation by a pharmacy or pharmacist.

22 **[(c)] (B)** A pharmacy benefits manager shall conduct an audit of a pharmacy or  
23 pharmacist under contract with the pharmacy benefits manager in accordance with this  
24 section.

25 **[(d)] (C)** (1) A pharmacy benefits manager may conduct an audit through an  
26 auditing entity.

27 (2) The Commissioner may adopt regulations to carry out this subsection.

28 **[(e)] (D)** A pharmacy benefits manager may not schedule an onsite audit to begin  
29 during the first 5 calendar days of a month unless requested by the pharmacy or  
30 pharmacist.

31 **[(f)] (E)** When conducting an audit, a pharmacy benefits manager shall:

1 (1) if the audit is onsite, provide written notice to the pharmacy or  
2 pharmacist at least 2 weeks before conducting the initial onsite audit for each audit cycle;

3 (2) employ the services of a pharmacist if the audit requires the clinical or  
4 professional judgment of a pharmacist;

5 (3) allow its auditors to enter the prescription area of a pharmacy only  
6 when accompanied by or authorized by a member of the pharmacy staff;

7 (4) allow a pharmacist or pharmacy to use any prescription, or authorized  
8 change to a prescription, that meets the requirements of COMAR 10.34.20.02 to validate  
9 claims submitted for reimbursement for dispensing of original and refill prescriptions;

10 (5) for purposes of validating the pharmacy record with respect to orders  
11 or refills of a drug, allow the pharmacy or pharmacist to use records of a hospital or a  
12 physician or other prescriber authorized by law that are:

13 (i) written; or

14 (ii) transmitted electronically or by any other means of  
15 communication authorized by contract between the pharmacy and the pharmacy benefits  
16 manager;

17 (6) accept a completed cash register transaction to serve as proof of delivery  
18 or pickup for a pharmacy customer unless there is contradictory information;

19 (7) audit each pharmacy and pharmacist under the same standards and  
20 parameters as other similarly situated pharmacies or pharmacists audited by the  
21 pharmacy benefits manager;

22 (8) only audit claims submitted or adjudicated within the 2-year period  
23 immediately preceding the audit, unless a longer period is authorized under federal or State  
24 law;

25 (9) deliver the preliminary audit report to the pharmacy or pharmacist  
26 within 120 calendar days after the completion of the audit, with reasonable extensions  
27 allowed;

28 (10) in accordance with subsection [(m)] (L) of this section, allow a  
29 pharmacy or pharmacist to produce documentation to address any discrepancy found  
30 during the audit; and

31 (11) deliver the final audit report to the pharmacy or pharmacist:

32 (i) within 6 months after delivery of the preliminary audit report if  
33 the pharmacy or pharmacist does not request an internal appeal under subsection [(m)]  
34 (L) of this section; or



1 (ii) within 30 days after the conclusion of the internal appeals  
2 process under subsection ~~[(m)]~~ **(L)** of this section if the pharmacy or pharmacist requests  
3 an internal appeal.

4 ~~[(g)]~~ **(F)** If a contract between a pharmacy or pharmacist and a pharmacy  
5 benefits manager specifies a period of time in which a pharmacy or pharmacist is allowed  
6 to withdraw and resubmit a claim and that period of time expires before the pharmacy  
7 benefits manager delivers a preliminary audit report that identifies discrepancies, the  
8 pharmacy benefits manager shall allow the pharmacy or pharmacist to withdraw and  
9 resubmit a claim within 30 days after:

10 (1) the preliminary audit report is delivered if the pharmacy or pharmacist  
11 does not request an internal appeal under subsection ~~[(m)]~~ **(L)** of this section; or

12 (2) the conclusion of the internal appeals process under subsection ~~[(m)]~~  
13 **(L)** of this section if the pharmacy or pharmacist requests an internal appeal.

14 ~~[(h)]~~ **(G)** During an audit, a pharmacy benefits manager may not disrupt the  
15 provision of services to the customers of a pharmacy.

16 ~~[(i)]~~ **(H)** (1) A pharmacy benefits manager may not:

17 (i) use the accounting practice of extrapolation to calculate  
18 overpayments or underpayments;

19 (ii) except as provided in paragraph (2) of this subsection:

20 1. share information from an audit with another pharmacy  
21 benefits manager; or

22 2. use information from an audit conducted by another  
23 pharmacy benefits manager;

24 (iii) recoup any funds from or charge any fees to a pharmacy or  
25 pharmacist for a prescription with regard to an incorrect days of supply calculation if the  
26 package size of the medication is unbreakable and the pharmacy benefits manager cannot  
27 accept the correct mathematically calculable days' supply during prescription adjudication;

28 (iv) have or request access to a pharmacy's or pharmacist's bank,  
29 credit card, or depository statements or data as it relates to cost-sharing; or

30 (v) audit claims that were reversed or for which there was no  
31 remuneration by the purchaser or cost to the pharmacy customer except if necessary to  
32 evaluate compliance to a contract.

1           (2) Paragraph (1)(ii) of this subsection does not apply to the sharing of  
2 information:

3                   (i) required by federal or State law;

4                   (ii) in connection with an acquisition or merger involving the  
5 pharmacy benefits manager; or

6                   (iii) at the payor's request or under the terms of the agreement  
7 between the pharmacy benefits manager and the payor.

8           **[(j)] (I)** A pharmacy benefits manager or purchaser may not audit more than  
9 125 prescriptions during a desk or site audit.

10           **[(k)] (J)** The recoupment of a claims payment from a pharmacy or pharmacist  
11 by a pharmacy benefits manager shall be based on an actual overpayment or denial of an  
12 audited claim unless the projected overpayment or denial is part of a settlement agreed to  
13 by the pharmacy or pharmacist.

14           **[(l)] (K)** (1) In this subsection, "overpayment" means a payment by the  
15 pharmacy benefits manager to a pharmacy or pharmacist that is greater than the rate or  
16 terms specified in the contract between the pharmacy or pharmacist and the pharmacy  
17 benefits manager at the time that the payment is made.

18                   (2) A clerical error, record-keeping error, typographical error, or  
19 scrivener's error in a required document or record may not constitute fraud or grounds for  
20 recoupment of a claims payment from a pharmacy or pharmacist by a pharmacy benefits  
21 manager if the prescription was otherwise legally dispensed and the claim was otherwise  
22 materially correct.

23                   (3) Notwithstanding paragraph (2) of this subsection, claims remain  
24 subject to recoupment of overpayment or payment of any discovered underpayment by the  
25 pharmacy benefits manager.

26           **[(m)] (L)** (1) A pharmacy benefits manager shall establish an internal appeals  
27 process under which a pharmacy or pharmacist may appeal any disputed claim in a  
28 preliminary audit report.

29                   (2) Under the internal appeals process, a pharmacy benefits manager shall  
30 allow a pharmacy or pharmacist to request an internal appeal within 30 working days after  
31 receipt of the preliminary audit report, with reasonable extensions allowed.

32                   (3) The pharmacy benefits manager shall include in its preliminary audit  
33 report a written explanation of the internal appeals process, including the name, address,  
34 and telephone number of the person to whom an internal appeal should be addressed.

1           (4) The decision of the pharmacy benefits manager on an appeal of a  
2 disputed claim in a preliminary audit report by a pharmacy or pharmacist shall be reflected  
3 in the final audit report.

4           (5) The pharmacy benefits manager shall deliver the final audit report to  
5 the pharmacy or pharmacist within 30 calendar days after conclusion of the internal  
6 appeals process.

7           ~~[(n)]~~ **(M)** (1) A pharmacy benefits manager may not recoup by setoff any  
8 money for an overpayment or denial of a claim until:

9                   (i) the pharmacy or pharmacist has an opportunity to review the  
10 pharmacy benefits manager's findings; and

11                   (ii) if the pharmacy or pharmacist concurs with the pharmacy  
12 benefits manager's findings of overpayment or denial, 30 working days have elapsed after  
13 the date the final audit report has been delivered to the pharmacy or pharmacist.

14           (2) If the pharmacy or pharmacist does not concur with the pharmacy  
15 benefits manager's findings of overpayment or denial, the pharmacy benefits manager may  
16 not recoup by setoff any money pending the outcome of an appeal under subsection ~~[(m)]~~  
17 **(L)** of this section.

18           (3) A pharmacy benefits manager shall remit any money due to a pharmacy  
19 or pharmacist as a result of an underpayment of a claim within 30 working days after the  
20 final audit report has been delivered to the pharmacy or pharmacist.

21           (4) Notwithstanding the provisions of paragraph (1) of this subsection, a  
22 pharmacy benefits manager may withhold future payments before the date the final audit  
23 report has been delivered to the pharmacy or pharmacist if the identified discrepancy for  
24 all disputed claims in a preliminary audit report for an individual audit exceeds \$25,000.

25           ~~[(o)]~~ **(N)** (1) A pharmacy benefits manager shall provide a pharmacy or  
26 pharmacist being audited with a phone number and, if available, access to a secure portal  
27 that the pharmacy or pharmacist may use to ask questions regarding the audit.

28           (2) An individual who is familiar with the audit shall respond to all  
29 inquiries made through a phone number or secure portal provided under paragraph (1) of  
30 this subsection within 3 business days after the inquiry was made.

31           ~~[(p)]~~ **(O)** (1) The pharmacy benefits manager shall give the pharmacy or  
32 pharmacist the option to provide requested audit documentation by postal mail, e-mail, or  
33 facsimile.

34           (2) If a document is requested regarding an audit, the pharmacy benefits  
35 manager shall provide a secure facsimile number and a mechanism for receiving secure  
36 e-mails.

1 (3) On or before October 1, 2025, a pharmacy benefits manager shall  
2 provide a mechanism for secure electronic communication for pharmacies and pharmacists  
3 to communicate with and submit documents to the auditing entity.

4 [(q)] (P) (1) The Commissioner may adopt regulations regarding:

5 (i) the documentation that may be requested during an audit; and

6 (ii) the process a pharmacy benefits manager may use to conduct an  
7 audit.

8 (2) On request of the Commissioner or the Commissioner's designee, a  
9 pharmacy benefits manager shall provide a copy of its audit procedures or internal appeals  
10 process.

11 15-1630.

12 (a) [This section applies only to a pharmacy benefits manager that provides  
13 pharmacy benefits management services on behalf of a carrier.

14 (b)] A pharmacy benefits manager shall establish a reasonable internal review  
15 process for a pharmacy to request the review of a failure to pay the contractual  
16 reimbursement amount of a submitted claim.

17 [(c)] (B) A pharmacy may request a pharmacy benefits manager to review a  
18 failure to pay the contractual reimbursement amount of a claim within 180 calendar days  
19 after the date the submitted claim was paid by the pharmacy benefits manager.

20 [(d)] (C) The pharmacy benefits manager shall give written notice of its review  
21 decision within 90 calendar days after receipt of a request for review from a pharmacy  
22 under this section.

23 [(e)] (D) If the pharmacy benefits manager determines through the internal  
24 review process established under subsection [(b)] (A) of this section that the pharmacy  
25 benefits manager underpaid a pharmacy, the pharmacy benefits manager shall pay any  
26 money due to the pharmacy within 30 working days after completion of the internal review  
27 process.

28 [(f)] (E) This section may not be construed to limit the ability of a pharmacy and  
29 a pharmacy benefits manager to contractually agree that a pharmacy may have more than  
30 180 calendar days to request an internal review of a failure of the pharmacy benefits  
31 manager to pay the contractual amount of a submitted claim.

32 SECTION 2. AND BE IT FURTHER ENACTED, That, on or before January 1, 2026,  
33 the Maryland Insurance Administration shall:

1           (1) convene a workgroup to review and make recommendations on  
2 provisions of State law regarding pharmacy benefits managers, specialty pharmacies, and  
3 antisteering, including:

4                   (i) § 15-847 of the Insurance Article related to specialty drug  
5 coverage and designated pharmacies;

6                   (ii) § 15-1611.1 of the Insurance Article related to required use of  
7 specific pharmacies or entities;

8                   (iii) § 15-1612 of the Insurance Article related to reimbursement; and

9                   (iv) any other provision of law that the Maryland Insurance  
10 Administration determines is relevant for review; and

11           (2) report to the Senate Finance Committee and the House Health and  
12 Government Operations Committee, in accordance with § 2-1257 of the State Government  
13 Article, on its recommendations, including any legislation necessary to carry out the  
14 recommendations.

15           SECTION ~~2~~ 3. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall  
16 take effect January 1, 2026.

17           SECTION 4. AND BE IT FURTHER ENACTED, That, except as provided in Section  
18 3 of this Act, this Act shall take effect June 1, 2025.

Approved:

---

Governor.

---

Speaker of the House of Delegates.

---

President of the Senate.